Eli Lilly Projects Lower-than-Expected Q4 Sales for Weight-Loss Drug Mounjaro
Eli Lilly (LLY) recently provided an update that has caught the attention of investors and market analysts alike. Despite the company’s popular weight-loss drug Zepbound and its diabetes treatment Mounjaro falling short of Wall Street … Read more